^
No biomarker
CMML
decitabine/cedazuridine
Sensitive: A1 - Approval
Astex Press Release - 4 days
Chr t(9;11)
CML
Tyrosine kinase inhibitor
Sensitive: C4 – Case Studies
SOHO 2021 - 3 weeks
BCR-ABL1 fusion
CML
dasatinib
Sensitive: A1 - Approval
No biomarker
CML
omacetaxine mepesuccinate
Sensitive: A1 - Approval
BCR-ABL1 T315I
CML
ponatinib
Sensitive: A1 - Approval
No biomarker
CML
ponatinib
Sensitive: A1 - Approval
ABL1 T315I
CML
ponatinib
Sensitive: A1 - Approval
Chr t(1;16)(q12;q11.2)
CML
ponatinib
Sensitive: A1 - Approval
No biomarker
CML
busulfan
Sensitive: A1 - Approval
No biomarker
CMML
azacitidine
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
nilotinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
bosutinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
imatinib
Sensitive: A1 - Approval
BCR-ABL1 V299L
CML
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
CML
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
CML
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
CML
nilotinib
Resistant: A2 - Guideline
No biomarker
CML
bosutinib
Sensitive: A2 - Guideline
No biomarker
CML
nilotinib
Sensitive: A2 - Guideline
No biomarker
CML
dasatinib
Sensitive: A2 - Guideline
No biomarker
CML
YD312
Sensitive: A2 - Guideline
BCR-ABL1 F317L
CML
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 fusion
CML
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
BCR-ABL1 V299L
CML
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 T315A
CML
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 F317I
CML
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 F317V
CML
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 F317C
CML
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 Y253H
CML
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 E255K
CML
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 E255V
CML
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 F359V
CML
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 F359C
CML
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 F359I
CML
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 G250E
CML
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 F317L
CML
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 F317L
CML
nilotinib
Sensitive: A2 - Guideline
BCR-ABL1 L248V
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 T315I
CML
ABL001
Sensitive: B - Late Trials
BCR-ABL1 T315I
CML
HQP1351
Sensitive: B - Late Trials
BCR-ABL1 fusion
CML
ABL001
Sensitive: B - Late Trials
BCR-ABL1 G250E
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 Q252H
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 E255K
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 F359C
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 Y253H
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 E355G
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 F359V
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 L387M
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 E459K
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 D276G
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 E279K
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 H396R
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 F486S
CML
dasatinib
Sensitive: B - Late Trials
BCR-ABL1 fusion
CML
ponatinib
Sensitive: C1 - Off-label
RUNX1 mutation
CMML
venetoclax
Sensitive: C2 – Inclusion Criteria
BCR-ABL1 mutation
CML
ABL001
Sensitive: C2 – Inclusion Criteria
CSF3R T618I
CML
ruxolitinib
Sensitive: C3 – Early Trials
ASXL1 mutation
CML
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
IDH2 mutation
CMML
venetoclax
Sensitive: C3 – Early Trials
BCR-ABL1 T315I
CML
imatinib
Resistant: C3 – Early Trials
BCR-ABL1 T315I
CML
dasatinib + nilotinib
Resistant: C3 – Early Trials
BCR-ABL1 T315I
CML
PF-114
Sensitive: C3 – Early Trials
CIP2A-H
CML
dasatinib
Resistant: C3 – Early Trials
miR-146a expression
CML
imatinib
Sensitive: C3 – Early Trials
IDH1 mutation
CMML
venetoclax
Sensitive: C3 – Early Trials
NPM1 mutation
CMML
venetoclax
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
CML
venetoclax + nilotinib
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
CML
venetoclax + bosutinib
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
CML
venetoclax + ponatinib
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
CML
venetoclax + dasatinib
Sensitive: C3 – Early Trials
BCR-ABL1 Q252H
CML
imatinib
Resistant: C3 – Early Trials
BCR-ABL1 M351T
CML
imatinib
Resistant: C3 – Early Trials
BCR-ABL1 L248V
CML
imatinib
Resistant: C3 – Early Trials
BCR-ABL1 F359V
CML
imatinib
Resistant: C3 – Early Trials
KRAS G12A
CML
GT19077
Sensitive: C3 – Early Trials
G0S2 overexpression
CML
YD312
Sensitive: C3 – Early Trials
DNMT3A deletion
CML
EGFR inhibitor
Resistant: C3 – Early Trials
ASXL1 deletion
CML
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
KDM4D mutation
CML
imatinib
Resistant: C3 – Early Trials
DNMT3A mutation
CML
YD312
Resistant: C3 – Early Trials
ASXL1 mutation
CML
YD312
Resistant: C3 – Early Trials
ABL1 T315I
CML
dasatinib
Resistant: C3 – Early Trials
ABL1 F317L
CML
dasatinib
Resistant: C3 – Early Trials
ABL1 T315I + M351T + L387M
CML
dasatinib
Resistant: C3 – Early Trials
ABL1 F359V
CML
dasatinib
Resistant: C3 – Early Trials
ABL1 G250E
CML
dasatinib
Resistant: C3 – Early Trials
ABL1 Y253H
CML
dasatinib
Resistant: C3 – Early Trials
ABL1 E255K
CML
dasatinib
Resistant: C3 – Early Trials
ABL1 D276G
CML
dasatinib
Resistant: C3 – Early Trials
ABL1 M351T
CML
dasatinib
Resistant: C3 – Early Trials
ABL1 L387M
CML
dasatinib
Resistant: C3 – Early Trials
BCR-ABL1 A397P
CML
dasatinib
Sensitive: C3 – Early Trials
BCR-ABL1 A397P
CML
imatinib
Resistant: C3 – Early Trials